In recent years, scholars have found that there were obvious changes in liver fat, increased adiponectin, and decreased TNF-α, IL-6, and resistin in patients with NAFLD after giving PPARγ agonist treatment [27]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.